AHISTON

Maa: Israel

Kieli: englanti

Lähde: Ministry of Health

Aktiivinen ainesosa:

CHLORPHENIRAMINE MALEATE

Saatavilla:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

ATC-koodi:

R06AB

Lääkemuoto:

TABLETS

Koostumus:

CHLORPHENIRAMINE MALEATE 2 MG

Antoreitti:

PER OS

Prescription tyyppi:

Required

Valmistaja:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Terapeuttinen ryhmä:

SUBSTITUTED ALKYLAMINES

Käyttöaiheet:

Symptomatic relief of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated urticaria and angioedema, amelioration of allergic reactions to blood or plasma, dermatographism, adjunctive therapy in anaplylactic reactions.

Valtuutus päivämäärä:

2014-07-31

Pakkausseloste

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor's prescription
only
AHISTON
®
TABLETS
COMPOSITION
Each tablet contains:
Chlorpheniramine maleate 2 mg
For
information
regarding
inactive
ingredients
and
allergens, see section 2 “Important information about
some of the ingredients of the medicine” and section 6
“Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE
MEDICINE.
This
leaflet
contains
concise
information
about the medicine. If you have additional questions,
refer to the doctor or the pharmacist.
This medicine has been prescribed for treatment of your
illness. Do not pass it on to others. It may harm them
even if it seems to you that their illness is similar.
The medicine is not intended for children under the age
of 6 years.
1. WHAT IS THE MEDICINE INTENDED FOR?
Relieving symptoms of seasonal allergy, such as: runny
nose and conjunctivitis, allergic skin reactions and other
allergic reactions.
THERAPEUTIC CLASS
Antihistamine
2. BEFORE USING THE MEDICINE
DO NOT USE THIS MEDICINE IF:
•
There is a known sensitivity to chlorpheniramine
maleate, to any of the other ingredients of the
medicine or to other antihistamines (see section 6
"Additional information").
•
You are taking antidepressants of the monoamine
oxidase inhibitors group (MAO inhibitors) or within
14 days of discontinuing use of these medicines.
•
You
are
taking
other
medicines
that
contain
antihistamines, including preparations for relieving
cold and cough.
SPECIAL WARNINGS REGARDING THE USE OF THE MEDICINE
BEFORE TREATMENT WITH AHISTON, INFORM YOUR DOCTOR
if you have had in the past or currently have:
•
High blood pressure
•
Heart problems
•
Epilepsy
•
Elevated intraocular pressure (glaucoma)
•
Prostate problems
•
Liver disease
•
Kidney disease
•
Bronchitis
•
Asthma
•
Bronchiectasis, widened bronchi
•
Chronic lung disease (difficulty breathing and cough
that does not go away)
DRUG INTERACTIONS
IF
YOU
ARE
T

Valmisteyhteenveto

Ahiston-2mg-tablets-LC+KL-Notification-SPC-12-2021
SUMMARYOF PRODUCT CHARACTERSITICS
1. NAME OF THE MEDICINAL PRODUCT
AHISTON
Tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains: Chlorpheniramine maleate 2 mg
Excipients with known effect:
Lactose content: 118 mg/tablet.
Sodium content: 0.14-0.21 mg/tablet.
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Tablet
Yellow, round tablet, scored in half on one side, engraved "IKA" on
the other.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Symptomatic relief of perennial and seasonal allergic rhinitis,
vasomotor rhinitis, allergic
conjunctivitis, mild uncomplicated urticaria and angioedema,
amelioration of allergic reactions
to blood or plasma, dermatographism, adjunctive therapy in
anaphylactic reactions.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral Administration only.
Do no exceed the stated dose or frequency of dosing.
It is recommended that this medicine be taken with or after food.
The adult dosage is 1-2 tablets, 3-4 times daily, as needed.
The dosage in children 6-12 years of age is 1/2-1 tablet 3-4 times
daily, as needed.
Not recommended for children under 6.
4.3 CONTRAINDICATIONS
Chlorphenamine is contra-indicated in patients who are hypersensitive
to antihistamines or to
any of the other ingredients.
The anticholinergic properties of chlorphenamine are intensified by
monoamine oxidase
inhibitors (MAOIs). Chlorphenamine is therefore contra-indicated in
patients who have been
treated with MAOIs within the last fourteen days.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Chlorphenamine in common with other drugs having anticholinergic
effects, should be used
with caution in epilepsy, raised intra-ocular pressure including
glaucoma, prostatic
hypertrophy; severe hypertension or cardiovascular disease;
bronchitis, bronchiectasis and
asthma; hepatic impairment; renal impairment Children and the elderly
are more likely to
experience the neurological anticholinergic effects and paradoxical
excitation (eg. increased
e